Income statement
USD
Annual
| Metric | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2M | -2M | -2M | -4M | -3M |
| EBITDA | -3M | -2M | -2M | -4M | -3M |
| Net Income | -3M | -2M | -6M | -7M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Technology
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProUroCare Medical Inc. (PUMD) is a Technology stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -30.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -30.8%, free cash flow -34.9% with operating margin 0.0% and ROIC 78.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PUMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PUMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PUMD Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PUMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$4.7M
+32.9% YoY
Free Cash Flow
-$1.1M
+65.3% YoY
Revenue Growth
+0.0%
EPS Growth
-30.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2M | -2M | -2M | -4M | -3M |
| EBITDA | -3M | -2M | -2M | -4M | -3M |
| Net Income | -3M | -2M | -6M | -7M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|
| Cash & Equivalents | 73K | 26K | 419K | 1M | 4K |
| Total Assets | 235K | 240K | 575K | 1M | 1M |
| Total Liabilities | 4M | 3M | 2M | 5M | 8M |
| Shareholder Equity | -4M | -3M | -2M | -4M | -7M |
| Total Debt | 1M | 2M | 1M | 3M | 5M |
| Net Debt | 1M | 2M | 982K | 2M | 5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+65.2% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
1M
+65.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
90.3%
Debt / Equity
-0.34x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.